February 13th 2025
This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.
February 13th 2025
February 10th 2025
FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment
November 29th 2023The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.
FDA Approves Defencath to Reduce Catheter Bloodstream Infections in Adults Receiving Hemodialysis
November 15th 2023On November 15, 2023, the FDA approved Defencath. The new drug can reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.